2-溴壬二酸二乙基酯 | 760-95-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-溴壬二酸二乙基酯
• 英文名称: diethyl 2-bromononanedioate
• 英文别名: diethyl α-bromononanedioate；α-Brom-azelainsaeure-diethylester；diethyl 2-bromoazelate；2-bromo-nonanedioic acid diethyl ester；2-Brom-nonandisaeure-diaethylester
• CAS: 760-95-2
• 化学式: C₁₃H₂₃BrO₄
• 分子量: 323.227
• InChiKey: ZMINIOSEUPWFEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-溴壬二酸二乙基酯 在 盐酸 、 硫酸 、 potassium carbonate 作用下， 以 甲醇 、 乙醚 、 苯 为溶剂， 生成 2-Methoxycarbonyl-5-oxo-1-cyclopentenheptansaeure
  参考文献：
  名称：

  dl-前列腺素E1的全合成。

  摘要：

  DOI：

  10.1021/jo00965a014
• 作为产物：
  描述：

  壬二酸 在 硫酸 作用下， 生成 2-溴壬二酸二乙基酯
  参考文献：
  名称：

  Synthesis of traumatoic (2e-dodecenedioic) acid from dodecanedioic acid

  摘要：

  DOI：

  10.1007/bf00957966

文献信息

• Cyclic exo amides
  申请人：Beecham Group Limited

  公开号：US04119726A1

  公开（公告）日：1978-10-10

  Compounds of formula (I): ##STR1## wherein: M IS 0 OR 1; n is 4 to 8; X is CO, protected CO, CROH in which R is hydrogen or C.sub.1-4 alkyl and in which the OH moiety may be protected; R.sub.1 is hydrogen, or CO.sub.2 R.sub.1 represents an ester group in Which the R.sub.1 moiety contains 1 to 12 carbon atoms; R.sub.3 is hydroxy or protected hydroxy; R.sub.2 and R.sub.4 are separately hydrogen, C.sub.1-9 alkyl, C.sub.5-8 cycloalkyl, C.sub.5-8 cycloalkyl-C.sub.1-6 alkyl, phenyl, phenyl C.sub.1-6 alkyl, naphthyl, naphthyl C.sub.1-6 alkyl, any of which phenyl or naphthyl moieties may be substituted by one or more halogen, trifluoromethyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or nitro groups, or R.sub.2 and R.sub.4 taken with the carbon atom to which they are joined represent C.sub.5-8 cycloalkyl; R.sub.5 is hydrogen, C.sub.1-4 alkyl or phenyl; and salts thereof; have useful pharmacological properties including anti-gastric secretion, bronchodilator and platelet aggregation inhibition activities.

  式(I)的化合物：其中：M为0或1；n为4至8；X为CO，保护的CO，CROH，其中R为氢或C.sub.1-4烷基，OH基团可能被保护；R.sub.1为氢，或CO.sub.2 R.sub.1代表一个酯基，其中R.sub.1基团含有1至12个碳原子；R.sub.3为羟基或保护的羟基；R.sub.2和R.sub.4分别为氢，C.sub.1-9烷基，C.sub.5-8环烷基，C.sub.5-8环烷基-C.sub.1-6烷基，苯基，苯基C.sub.1-6烷基，萘基，萘基C.sub.1-6烷基，其中苯基或萘基可能被一个或多个卤素，三氟甲基，C.sub.1-6烷基，C.sub.1-6烷氧基或硝基取代，或R.sub.2和R.sub.4与它们连接的碳原子一起代表C.sub.5-8环烷基；R.sub.5为氢，C.sub.1-4烷基或苯基；及其盐；具有有用的药理学特性，包括抗胃分泌、支气管扩张剂和抑制血小板聚集活性。
• Synthesis and Inhibitory Activity on Platelet Aggregation of 13′-Aza and Other ω-Chain Modified BW245C Analogues
  作者：Paur Barraclough、Michael Brockwell、A. Gordon Caldwell、Derek A. Demaine、C. John Harris、W. Richard King、Ray J. Stepney、Clifford J. Wharton、Brendan J. R. Whittle

  DOI：10.1002/ardp.19943270508

  日期：——

  BW245C analogues which have 15′‐keto, ‐oximino, ‐sulphinyl, ‐sulphonyl, ‐methyl, ‐1‐adamantyl, 14′‐hydroxy, 16′‐hydroxy, 13′‐14′‐NHCH,‐ NH‐CH2, or ‐NH‐CO groups have been synthesized and evaluated for their activity in inhibiting platelet aggregation and for their cardiovascular actions: the 13′‐aza analogues 13 and 14 are more potent inhibitors of human platelet aggregation than BW245C (0.3, 0.6

  BW245C 类似物，具有 15'-酮基、-肟基、-亚磺酰基、-磺酰基、-甲基、-1-金刚烷基、14'-羟基、16'-羟基、13'-14'-NHCH、-NH , 或 -NH -CO 基团已被合成并评估其抑制血小板聚集和心血管作用的活性：13' - 氮杂类似物 13 和 14 是比 BW245C 更有效的人血小板聚集抑制剂（0.3、0.6 和 0.2 xPGl2）和这些对血小板聚集的抑制活性在体外孵育时增加。更详细地研究了 13 (BW68C) 和 14 (BW361C) 的前列腺素模拟特性，发现它们的血小板抑制和血管舒张作用比 BW245C 的持续时间更长。对 BW245C ω - 链的所有其他修饰都导致了效力较低或无活性的化合物。
• Pharmaceutically active compounds, preparation thereof, intermediates
  申请人：Beecham Group Limited

  公开号：US04156730A1

  公开（公告）日：1979-05-29

  A compound of formula (I): ##STR1## wherein: M IS 0 OR 1; N is 4 to 8; A is hydrogen, and when m is 0 and R.sub.5 is methyl it may also be methyl or a group CO.sub.2 B wherein B is hydrogen or CO.sub.2 B represents an ester group in which the B moiety contains from 1 to 12 carbon atoms; X is CO, protected CO, CROH in which R is hydrogen or C.sub.1-4 alkyl and in which the OH moiety may be protected; R.sub.1 is hydrogen, or CO.sub.2 R.sub.1 represents an ester group in which the R.sub.1 moiety contains 1 to 12 carbon atoms; R.sub.4 is hydrogen, C.sub.1-9 alkyl, C.sub.5-8 cycloalkyl, C.sub.5-8 cycloalkyl-C.sub.1-6 alkyl, phenyl, phenyl C.sub.1-6 alkyl, naphthyl, naphthyl C.sub.1-6 alkyl, any of which phenyl or naphthyl moieties may be substituted by one or more halogen, trifluoromethyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, or nitro groups; D is a group --CH.sub.2 --CH(R.sub.6)--CH(R.sub.7)--C(R.sub.2)(R.sub.3)--, a group --CH.sub.2 --CH(R.sub.6)--CH(R.sub.7)--CH(R.sub.8)--C(R.sub.2)(R.sub.3)--, a group --CH.sub.2 --CH(R.sub.6)--CH(R.sub.7)--CH(R.sub.8)--CH(R.sub.8.sup.1)--C(R.sub.2)(R.s ub.3)-- or a group --CH.sub.2 --C(R.sub.10)(R.sub.3)-- wherein R.sub.2 is hydrogen, C.sub.1-4 alkyl or phenyl; R.sub.3 is hydroxy or protected hydroxy; R.sub.6, R.sub.7, R.sub.8 and R.sub.8.sup.1 are hydrogen, C.sub.1-4 alkyl or phenyl; and R.sub.10 is hydrogen, C.sub.1-4 alkyl or phenyl; and R.sub.5 is hydrogen, and when m is 0 it may also be methyl; and salts thereof; have a range of pharmacological activities similar to those shown by the natural prostaglandins, but these activities tend to be rather more selective.

  化合物的化学式（I）：##STR1##其中：M为0或1；N为4至8；A为氢，当m为0且R.sub.5为甲基时，也可以是甲基或CO.sub.2 B基团，其中B为氢或CO.sub.2 B表示的是一个酯基团，其中B基团含有1至12个碳原子；X为CO，保护的CO，CROH，其中R为氢或C.sub.1-4烷基，OH基团可能被保护；R.sub.1为氢，或CO.sub.2 R.sub.1表示的是一个酯基团，其中R.sub.1基团含有1至12个碳原子；R.sub.4为氢，C.sub.1-9烷基，C.sub.5-8环烷基，C.sub.5-8环烷基-C.sub.1-6烷基，苯基，苯基-C.sub.1-6烷基，萘基，萘基-C.sub.1-6烷基，其中苯基或萘基可能被一个或多个卤素，三氟甲基，C.sub.1-6烷基，C.sub.1-6烷氧基或硝基取代；D为一个基团--CH.sub.2--CH(R.sub.6)--CH(R.sub.7)--C(R.sub.2)(R.sub.3)--，一个基团--CH.sub.2--CH(R.sub.6)--CH(R.sub.7)--CH(R.sub.8)--C(R.sub.2)(R.sub.3)--，一个基团--CH.sub.2--CH(R.sub.6)--CH(R.sub.7)--CH(R.sub.8)--CH(R.sub.8.sup.1)--C(R.sub.2)(R.sub.3)--或一个基团--CH.sub.2--C(R.sub.10)(R.sub.3)--其中R.sub.2为氢，C.sub.1-4烷基或苯基；R.sub.3为羟基或保护的羟基；R.sub.6，R.sub.7，R.sub.8和R.sub.8.sup.1为氢，C.sub.1-4烷基或苯基；R.sub.10为氢，C.sub.1-4烷基或苯基；R.sub.5为氢，当m为0时也可以是甲基；及其盐；具有一系列类似于天然前列腺素所显示的药理活性，但这些活性往往更具选择性。
• Oxy-alkylamino carboxylic esters
  申请人：Beecham Group Limited

  公开号：US04299970A1

  公开（公告）日：1981-11-10

  Compounds of formula (I): ##STR1## wherein: X is CO, protected CO, CROH in which R is hydrogen or C.sub.1-4 alkyl and in which the OH moiety may be protected; Y is CH.sub.2 CH.sub.2 or CH.dbd.CH; Z is CO or CH.sub.2 ; n is 1 to 8; m is 1, 2 or 3; R.sub.1 is hydrogen, CH.sub.2 OH, CH.sub.2 OH in which the OH moiety is protected, CO.sub.2 W wherein W is hydrogen or CO.sub.2 W represents an ester group in which the ester moiety contains from 1 to 12 carbon atoms, or CONH.sub.2 ; R.sub.2 is hydrogen, C.sub.1-4 alkyl, or taken together with R.sub.3 and the carbon atom to which it is attached represents a carbonyl group; R.sub.3 is hydrogen, hydroxy or protected hydroxy; R.sub.4 is hydrogen or C.sub.1-9 alkyl; and salts thereof--have useful pharmacological properties.

  式(I)的化合物：其中：X为CO，被保护的CO，CR-OH，其中R为氢或C.sub.1-4烷基，且OH基团可能被保护；Y为CH.sub.2 CH.sub.2或CH.dbd.CH；Z为CO或CH.sub.2；n为1至8；m为1、2或3；R.sub.1为氢，CH.sub.2 OH，被保护的CH.sub.2 OH，CO.sub.2 W，其中W为氢或CO.sub.2 W代表一个酯基，其中酯基含有1至12个碳原子，或CONH.sub.2；R.sub.2为氢，C.sub.1-4烷基，或与R.sub.3和其连接的碳原子一起代表一个羰基；R.sub.3为氢，羟基或被保护的羟基；R.sub.4为氢或C.sub.1-9烷基；及其盐--具有有用的药理学性质。
• 2,4 Pyrrolidinediones
  申请人：Beecham Group Limited

  公开号：US04138407A1

  公开（公告）日：1979-02-06

  Compounds of formula (I): ##STR1## wherein: m is 1 or 2; n is 4 to 8; X is CO, protected CO, or CROH wherein R is hydrogen or C.sub.1-4 alkyl and wherein the OH moiety may be protected; R.sub.1 is hydrogen or CO.sub.2 R.sub.1 represents an ester group in which the R.sub.1 moiety contains from 1 to 12 carbon atoms; R.sub.3 is hydroxy, or protected hydroxy; R.sub.2 and R.sub.4 are separately hydrogen, C.sub.1-9 alkyl, C.sub.5-8 cycloalkyl, C.sub.5-8 cycloalkyl-C.sub.1-6 alkyl, phenyl, phenyl C.sub.1-6 alkyl, naphthyl, naphthyl C.sub.1-6 alkyl, any of which phenyl or naphthyl moieties may be substituted by one or more halogen, trifluoromethyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or nitro groups; or R.sub.2 and R.sub.4 taken with the carbon atom to which they are joined represent a C.sub.5-8 cycloalkyl group; and salts thereof; except that when one of R.sub.2 and R.sub.4 is hydrogen or C.sub.1-4 alkyl when the other of R.sub.2 and R.sub.4 cannot be hydrogen or C.sub.1-9 alkyl; have useful pharmacological properties including antigastric secretion, bronchodilator and platelet aggregation inhibition activities.

  式(I)的化合物：其中：m为1或2；n为4至8；X为CO，受保护的CO或CROH，其中R为氢或C.sub.1-4烷基，OH基团可以受保护；R.sub.1为氢或CO.sub.2，R.sub.1代表一个酯基，其中R.sub.1基团含有1至12个碳原子；R.sub.3为羟基或受保护的羟基；R.sub.2和R.sub.4分别为氢、C.sub.1-9烷基、C.sub.5-8环烷基、C.sub.5-8环烷基-C.sub.1-6烷基、苯基、苯基C.sub.1-6烷基、萘基、萘基C.sub.1-6烷基，其中苯基或萘基可以被一个或多个卤素、三氟甲基、C.sub.1-6烷基、C.sub.1-6烷氧基或硝基取代；或者R.sub.2和R.sub.4与它们连接的碳原子一起代表一个C.sub.5-8环烷基基团；及其盐；除非R.sub.2和R.sub.4中的一个为氢或C.sub.1-4烷基时，另一个不能为氢或C.sub.1-9烷基；具有有用的药理特性，包括抗胃分泌、支气管扩张剂和抑制血小板聚集活性。